Skip to main content
. Author manuscript; available in PMC: 2018 Feb 28.
Published in final edited form as: J Am Coll Cardiol. 2017 Feb 28;69(8):968–977. doi: 10.1016/j.jacc.2016.11.067

FIGURE 3. HF Hospitalization and β-blocker Use.

FIGURE 3

In 322 subjects who used β-blockers at baseline and continued at 6 months or were using β-blockers at 6 months, there was no significant difference in overall survival from heart failure (HF) hospitalization in patients whether IgG3 was present (A) but the presence of non-IgG3 was associated with worse overall survival (B). No differences were observed in the negative group (C). Abbreviations as in Figures 1 and 2.